ChenGuang Biotech Group Co., Ltd. (300138.SZ)
CNY 10.92
(1.11%)
CNY 10.92
(1.11%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 4.21 Billion CNY | 48.52% |
| 2022 | 2.84 Billion CNY | 16.16% |
| 2021 | 2.44 Billion CNY | 17.81% |
| 2020 | 2.07 Billion CNY | -5.55% |
| 2019 | 2.19 Billion CNY | 70.55% |
| 2018 | 1.28 Billion CNY | 43.11% |
| 2017 | 900.29 Million CNY | 38.13% |
| 2016 | 651.77 Million CNY | 107.83% |
| 2015 | 313.6 Million CNY | -6.15% |
| 2014 | 334.16 Million CNY | -30.38% |
| 2013 | 480 Million CNY | 70.6% |
| 2012 | 281.35 Million CNY | 309.48% |
| 2011 | 68.71 Million CNY | -65.7% |
| 2010 | 200.29 Million CNY | 32.54% |
| 2009 | 151.11 Million CNY | 114.92% |
| 2008 | 70.31 Million CNY | 87.63% |
| 2007 | 37.47 Million CNY | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 4.92 Billion CNY | 16.86% |
| 2024 Q2 | 4.52 Billion CNY | -8.17% |
| 2024 Q3 | 3.49 Billion CNY | -22.77% |
| 2023 Q2 | 3.11 Billion CNY | -9.16% |
| 2023 Q1 | 3.42 Billion CNY | 20.67% |
| 2023 Q3 | 3.29 Billion CNY | 5.89% |
| 2023 Q4 | 4.21 Billion CNY | 27.95% |
| 2023 FY | 4.21 Billion CNY | 48.52% |
| 2022 FY | 2.84 Billion CNY | 16.16% |
| 2022 Q2 | 2.46 Billion CNY | -0.97% |
| 2022 Q3 | 2.6 Billion CNY | 6.03% |
| 2022 Q4 | 2.84 Billion CNY | 8.89% |
| 2022 Q1 | 2.48 Billion CNY | 1.6% |
| 2021 Q3 | 955.53 Million CNY | -31.14% |
| 2021 FY | 2.44 Billion CNY | 17.81% |
| 2021 Q2 | 1.38 Billion CNY | -11.9% |
| 2021 Q1 | 1.57 Billion CNY | -24.11% |
| 2021 Q4 | 2.44 Billion CNY | 155.89% |
| 2020 Q2 | 2.34 Billion CNY | 1.87% |
| 2020 Q3 | 1.71 Billion CNY | -26.73% |
| 2020 FY | 2.07 Billion CNY | -5.55% |
| 2020 Q4 | 2.07 Billion CNY | 20.78% |
| 2020 Q1 | 2.3 Billion CNY | 4.77% |
| 2019 Q2 | 1.09 Billion CNY | -13.72% |
| 2019 FY | 2.19 Billion CNY | 70.55% |
| 2019 Q3 | 1.2 Billion CNY | 10.98% |
| 2019 Q4 | 2.19 Billion CNY | 81.6% |
| 2019 Q1 | 1.26 Billion CNY | -1.92% |
| 2018 Q3 | 1 Billion CNY | -1.89% |
| 2018 Q1 | 957.49 Million CNY | 6.35% |
| 2018 FY | 1.28 Billion CNY | 43.11% |
| 2018 Q4 | 1.28 Billion CNY | 27.82% |
| 2018 Q2 | 1.02 Billion CNY | 7.3% |
| 2017 Q3 | 252.14 Million CNY | -53.77% |
| 2017 Q4 | 900.29 Million CNY | 257.05% |
| 2017 FY | 900.29 Million CNY | 38.13% |
| 2017 Q1 | 524.06 Million CNY | -19.59% |
| 2017 Q2 | 545.37 Million CNY | 4.07% |
| 2016 Q4 | 651.77 Million CNY | 193.95% |
| 2016 Q3 | 221.73 Million CNY | -10.63% |
| 2016 Q2 | 248.09 Million CNY | -23.44% |
| 2016 FY | 651.77 Million CNY | 107.83% |
| 2016 Q1 | 324.07 Million CNY | 3.34% |
| 2015 Q1 | 295.26 Million CNY | -11.64% |
| 2015 Q3 | 203.94 Million CNY | -4.53% |
| 2015 FY | 313.6 Million CNY | -6.15% |
| 2015 Q4 | 313.6 Million CNY | 53.77% |
| 2015 Q2 | 213.62 Million CNY | -27.65% |
| 2014 Q2 | 328.28 Million CNY | -26.95% |
| 2014 Q4 | 334.16 Million CNY | 64.27% |
| 2014 Q3 | 203.42 Million CNY | -38.03% |
| 2014 Q1 | 449.42 Million CNY | -6.37% |
| 2014 FY | 334.16 Million CNY | -30.38% |
| 2013 Q2 | 350.66 Million CNY | -1.42% |
| 2013 FY | 480 Million CNY | 70.6% |
| 2013 Q4 | 480 Million CNY | 38.73% |
| 2013 Q3 | 346 Million CNY | -1.33% |
| 2013 Q1 | 355.7 Million CNY | 26.42% |
| 2012 Q3 | 186.45 Million CNY | -6.59% |
| 2012 Q4 | 281.35 Million CNY | 50.89% |
| 2012 Q1 | 112.97 Million CNY | 64.42% |
| 2012 FY | 281.35 Million CNY | 309.48% |
| 2012 Q2 | 199.61 Million CNY | 76.69% |
| 2011 Q1 | 186.37 Million CNY | -6.95% |
| 2011 Q2 | 119.67 Million CNY | -35.79% |
| 2011 Q4 | 68.71 Million CNY | -10.35% |
| 2011 FY | 68.71 Million CNY | -65.7% |
| 2011 Q3 | 76.64 Million CNY | -35.96% |
| 2010 Q3 | 185.18 Million CNY | 31.91% |
| 2010 Q4 | 200.29 Million CNY | 8.16% |
| 2010 FY | 200.29 Million CNY | 32.54% |
| 2010 Q2 | 140.39 Million CNY | 0.0% |
| 2009 Q4 | 151.11 Million CNY | 0.0% |
| 2009 FY | 151.11 Million CNY | 114.92% |
| 2008 FY | 70.31 Million CNY | 87.63% |
| 2007 FY | 37.47 Million CNY | 0.0% |